Often, single‐arm trials are used in phase II to gather the first evidence of an oncological
drug's efficacy, with drug activity determined through tumour response using the RECIST …

Background Adrenal cortical carcinoma (ACC) is a rare cancer with treatment options of
limited efficacy, and poor prognosis if metastatic. AT-101 is a more potent inhibitor of B cell …

Drug development for tuberculosis (TB) faces numerous practical obstacles, including the
need for combination treatment with at least three drugs, reliance on possibly …

We need improved, translatable and predictive tumour models for the evaluation of
response and the evolution of resistance to targeted therapeutics. We provide a review of …

Current lung cancer clinical research focuses on biomarkers and personalized treatment
strategies. Adaptive clinical trial designs have gained significant ground due to their …

Many new medical treatments are developed using powerful technologies, such as
microarrays, gene sequencing, or cytometric machines that can rapidly identify dozens of …

Background and aim The primary aim of this study was to determine whether randomised
phase 2 (RP2) trials predict phase 3 trial outcome better than single arm phase 2 (SAP2) …

Recent advances in the management of diffuse pleural mesothelioma (DPM) have
increased interest in prognostication and risk stratification on the basis that maximum benefit …

IntroductionAlthough classical randomized clinical trials (RCTs) are the gold standard for
proof of drug efficacy, randomized discontinuation trials (RDTs), sometimes called …

Single-arm studies are typically used in phase II of clinical trials, whose main objective is to
determine whether a new treatment warrants further testing in a randomized phase III trial …